MESA LABORATORIES INC (MLAB)
US59064R1095 - Common Stock
We assign a fundamental rating of 5 out of 10 to MLAB. MLAB was compared to 58 industry peers in the Life Sciences Tools & Services industry. MLAB has only an average score on both its financial health and profitability. MLAB has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
MLAB had positive earnings in the past year.
MLAB had a positive operating cash flow in the past year.
In the past 5 years MLAB has always been profitable.
Each year in the past 5 years MLAB had a positive operating cash flow.
1.2 Ratios
MLAB has a better Return On Assets (0.13%) than 67.24% of its industry peers.
The Return On Equity of MLAB (0.23%) is better than 70.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.13% | ||
| ROE | 0.23% | ||
| ROIC | N/A |
ROA(3y)0.32%
ROA(5y)1.21%
ROE(3y)0.51%
ROE(5y)1.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MLAB has a better Profit Margin (0.44%) than 68.97% of its industry peers.
In the last couple of years the Profit Margin of MLAB has declined.
In the last couple of years the Operating Margin of MLAB has declined.
MLAB has a better Gross Margin (61.02%) than 86.21% of its industry peers.
In the last couple of years the Gross Margin of MLAB has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 0.44% | ||
| GM | 61.02% |
OM growth 3Y-38.97%
OM growth 5Y-38.14%
PM growth 3Y-28.09%
PM growth 5YN/A
GM growth 3Y3.44%
GM growth 5Y1.46%
2. Health
2.1 Basic Checks
MLAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
MLAB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MLAB has more shares outstanding
The debt/assets ratio for MLAB has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.69, we must say that MLAB is in the distress zone and has some risk of bankruptcy.
MLAB's Altman-Z score of 1.69 is in line compared to the rest of the industry. MLAB outperforms 44.83% of its industry peers.
MLAB has a debt to FCF ratio of 5.72. This is a neutral value as MLAB would need 5.72 years to pay back of all of its debts.
The Debt to FCF ratio of MLAB (5.72) is better than 68.97% of its industry peers.
MLAB has a Debt/Equity ratio of 0.58. This is a neutral value indicating MLAB is somewhat dependend on debt financing.
MLAB has a Debt to Equity ratio of 0.58. This is in the lower half of the industry: MLAB underperforms 68.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | 5.72 | ||
| Altman-Z | 1.69 |
ROIC/WACCN/A
WACC10.97%
2.3 Liquidity
A Current Ratio of 2.68 indicates that MLAB has no problem at all paying its short term obligations.
MLAB has a Current ratio (2.68) which is in line with its industry peers.
A Quick Ratio of 1.86 indicates that MLAB should not have too much problems paying its short term obligations.
The Quick ratio of MLAB (1.86) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.68 | ||
| Quick Ratio | 1.86 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 158.62% over the past year.
MLAB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -43.54% yearly.
Looking at the last year, MLAB shows a decrease in Revenue. The Revenue has decreased by -4.27% in the last year.
MLAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.89% yearly.
EPS 1Y (TTM)158.62%
EPS 3Y-42.46%
EPS 5Y-43.54%
EPS growth Q2Q387.5%
Revenue 1Y (TTM)-4.27%
Revenue growth 3Y23.01%
Revenue growth 5Y17.89%
Revenue growth Q2Q-1.5%
3.2 Future
Based on estimates for the next years, MLAB will show a very strong growth in Earnings Per Share. The EPS will grow by 230.25% on average per year.
MLAB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.38% yearly.
EPS Next Y-135.06%
EPS Next 2Y54.62%
EPS Next 3Y230.25%
EPS Next 5YN/A
Revenue Next Year-4.23%
Revenue Next 2Y2.75%
Revenue Next 3Y5.38%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 718.94, the valuation of MLAB can be described as expensive.
60.34% of the companies in the same industry are more expensive than MLAB, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of MLAB to the average of the S&P500 Index (28.15), we can say MLAB is valued expensively.
MLAB is valuated quite expensively with a Price/Forward Earnings ratio of 319.53.
MLAB's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.20, MLAB is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 718.94 | ||
| Fwd PE | 319.53 |
4.2 Price Multiples
75.86% of the companies in the same industry are more expensive than MLAB, based on the Enterprise Value to EBITDA ratio.
96.55% of the companies in the same industry are more expensive than MLAB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.18 | ||
| EV/EBITDA | 25.1 |
4.3 Compensation for Growth
MLAB's earnings are expected to grow with 230.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y54.62%
EPS Next 3Y230.25%
5. Dividend
5.1 Amount
MLAB has a yearly dividend return of 0.53%, which is pretty low.
MLAB's Dividend Yield is rather good when compared to the industry average which is at 0.63. MLAB pays more dividend than 96.55% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.33, MLAB's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.53% |
5.2 History
The dividend of MLAB decreases each year by -0.17%.
MLAB has paid a dividend for at least 10 years, which is a reliable track record.
MLAB has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-0.17%
Div Incr Years0
Div Non Decr Years16
5.3 Sustainability
MLAB pays out 363.95% of its income as dividend. This is not a sustainable payout ratio.
DP363.95%
EPS Next 2Y54.62%
EPS Next 3Y230.25%
MESA LABORATORIES INC
NASDAQ:MLAB (5/17/2024, 7:13:29 PM)
After market: 122.22 0 (0%)122.22
+1.61 (+1.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap658.77M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.53% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 718.94 | ||
| Fwd PE | 319.53 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.13% | ||
| ROE | 0.23% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | 0.44% | ||
| GM | 61.02% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.68 | ||
| Quick Ratio | 1.86 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)158.62%
EPS 3Y-42.46%
EPS 5Y
EPS growth Q2Q
EPS Next Y-135.06%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-4.27%
Revenue growth 3Y23.01%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y